102 related articles for article (PubMed ID: 11472206)
21. Synthesis and cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of heterocycle condensed purines.
Suzuki H; Yamamoto M; Shimura S; Miyamoto K; Yamamoto K; Sawanishi H
Chem Pharm Bull (Tokyo); 2002 Sep; 50(9):1163-8. PubMed ID: 12237530
[TBL] [Abstract][Full Text] [Related]
22. 7-(Ethoxycarbonyl)-6,8-dimethyl-2-phenyl-1(2H)-phthalazinone derivatives: synthesis and inhibitory effects on platelet aggregation.
Sugimoto A; Tanaka H; Eguchi Y; Ito S; Takashima Y; Ishikawa M
J Med Chem; 1984 Oct; 27(10):1300-5. PubMed ID: 6090662
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and biological evaluation of new phosphodiesterase type 4 inhibitors.
Ochiai H; Odagaki Y; Ohtani T; Ishida A; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Kobayashi K; Nakai H; Toda M
Bioorg Med Chem; 2004 Oct; 12(19):5063-78. PubMed ID: 15351390
[TBL] [Abstract][Full Text] [Related]
24. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
[No Abstract] [Full Text] [Related]
25. First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives.
Provins L; Christophe B; Danhaive P; Dulieu J; Durieu V; Gillard M; Lebon F; Lengelé S; Quéré L; van Keulen B
Bioorg Med Chem Lett; 2006 Apr; 16(7):1834-9. PubMed ID: 16439121
[TBL] [Abstract][Full Text] [Related]
26. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4).
Thompson WJ; Ashikaga T; Kelly JJ; Liu L; Zhu B; Vemavarapu L; Strada SJ
Biochem Pharmacol; 2002 Feb; 63(4):797-807. PubMed ID: 11992650
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of neutrophilic inflammation inhibitors.
Bruno O; Brullo C; Arduino N; Schenone S; Ranise A; Bondavalli F; Ottonello L; Dapino P; Dallegri F
Farmaco; 2004 Mar; 59(3):223-35. PubMed ID: 14987986
[TBL] [Abstract][Full Text] [Related]
28. Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse.
Cherry JA; Thompson BE; Pho V
Biochim Biophys Acta; 2001 Mar; 1518(1-2):27-35. PubMed ID: 11267656
[TBL] [Abstract][Full Text] [Related]
29. Benzofuran based PDE4 inhibitors.
McGarry DG; Regan JR; Volz FA; Hulme C; Moriarty KJ; Djuric SW; Souness JE; Miller BE; Travis JJ; Sweeney DM
Bioorg Med Chem; 1999 Jun; 7(6):1131-9. PubMed ID: 10428384
[TBL] [Abstract][Full Text] [Related]
30. A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo.
Cooper N; Teixeira MM; Warneck J; Miotla JM; Wills RE; Macari DM; Gristwood RW; Hellewell PG
Br J Pharmacol; 1999 Apr; 126(8):1863-71. PubMed ID: 10372831
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus.
Zhang HT; Zhao Y; Huang Y; Dorairaj NR; Chandler LJ; O'Donnell JM
Neuropsychopharmacology; 2004 Aug; 29(8):1432-9. PubMed ID: 15114341
[TBL] [Abstract][Full Text] [Related]
32. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
[TBL] [Abstract][Full Text] [Related]
33. Practical enantioselective process for a chiral phosphodiesterase-4 inhibitor.
Chen CY
Curr Opin Drug Discov Devel; 2005 Nov; 8(6):709-22. PubMed ID: 16312147
[TBL] [Abstract][Full Text] [Related]
34. Phosphodiesterase 4 inhibition synergizes with relaxin signaling to promote decidualization of human endometrial stromal cells.
Bartsch O; Bartlick B; Ivell R
J Clin Endocrinol Metab; 2004 Jan; 89(1):324-34. PubMed ID: 14715868
[TBL] [Abstract][Full Text] [Related]
35. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P
Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252
[No Abstract] [Full Text] [Related]
36. Substituted aminopyridines as potent and selective phosphodiesterase-4 inhibitors.
Côté B; Frenette R; Prescott S; Blouin M; Brideau C; Ducharme Y; Friesen RW; Laliberté F; Masson P; Styhler A; Girard Y
Bioorg Med Chem Lett; 2003 Feb; 13(4):741-4. PubMed ID: 12639571
[TBL] [Abstract][Full Text] [Related]
37. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.
Makhay MM; Houslay MD; O'Donnell JM
Psychopharmacology (Berl); 2001 Nov; 158(3):297-304. PubMed ID: 11713620
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
39. Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.
Dal Piaz V; Giovannoni MP; Castellana C; Palacios JM; Beleta J; Doménech T; Segarra V
J Med Chem; 1997 May; 40(10):1417-21. PubMed ID: 9154964
[TBL] [Abstract][Full Text] [Related]
40. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
